Esperion Therapeutics, Inc.
(NASDAQ : ESPR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 2.91%69.000.0%$1713.15m
GILDGilead Sciences, Inc. -0.22%73.341.0%$1486.09m
AMGNAmgen, Inc. 0.73%226.431.3%$647.45m
REGNRegeneron Pharmaceuticals, Inc. 1.59%569.912.5%$560.12m
VRTXVertex Pharmaceuticals, Inc. 0.12%284.961.9%$540.88m
NVAXNovavax, Inc. -7.91%46.11102.0%$530.71m
BIIBBiogen, Inc. 0.02%304.531.6%$447.72m
ILMNIllumina, Inc. 1.51%354.703.5%$344.73m
SRNESorrento Therapeutics, Inc. 0.80%5.071.8%$271.93m
SGENSeattle Genetics, Inc. 1.02%155.776.1%$227.64m
ALXNAlexion Pharmaceuticals, Inc. 0.36%101.502.0%$215.96m
CODXCo-Diagnostics, Inc. 2.94%18.550.0%$192.06m
AAgilent Technologies, Inc. 5.24%84.981.6%$187.17m
IMMUImmunomedics, Inc. -0.69%34.4711.0%$184.11m
MGNXMacroGenics, Inc. 0.84%25.376.2%$182.51m

Company Profile

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.